SONUS Pharmaceuticals, Inc. (NASDAQ: SNUS) is engaged in the research and development of proprietary ultrasound contrast agents and drug delivery systems for use in the diagnosis and treatment of heart disease, cancer and other debilitating conditions. Sonus went public in 1995.